Skip to content

Vouchers vs. Prizes for Methadone Patients - 1

Vouchers vs. Prizes for Methadone Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00249522
Enrollment
76
Registered
2005-11-07
Start date
2003-08-31
Completion date
2006-01-31
Last updated
2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Abuse

Keywords

contingency management, substance abuse treatment

Brief summary

The purpose of this study is to compare voucher-based contingency management (CM) procedures to a lower-cost CM system that provides opportunities to win prizes. Cocaine-dependent outpatients are randomly assigned to (a) standard treatment, (b) standard treatment plus voucher CM for abstinence, defined by negative breath and urinalysis test results, or (c) standard treatment plus prize CM for abstinence, defined by negative breath and urinalysis test results. Urine and breath samples are collected 3x/week during Weeks 1-3, 2x/week during Weeks 4-6 and 1x/week during Weeks 7-12. Follow-up interviews are conducted 1,3,6 and 9 months following intake during which substance use and psychosocial functioning are assessed.

Interventions

BEHAVIORALContingency management

Sponsors

UConn Health
CollaboratorOTHER
National Institute on Drug Abuse (NIDA)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \> 18 years * current DSM-IV diagnosis of cocaine dependence * maintained on a stable dose of methadone for \>1 month * willing to sign informed consent * English speaking

Exclusion criteria

* serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, or substantial suicide risk) on the basis of history or medical examination * dementia (\<23 on the Mini Mental State Exam) * in recovery from pathological gambling as determined by DSM-IV criteria

Design outcomes

Primary

MeasureTime frame
Drug usebaseline and each follow-up

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026